stockrowBio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO
Alert me
Bio-Rad Laboratories, Inc. (BIO) Return on equity
Bio-Rad Laboratories, Inc.'s return on equity over the twelve months to 30 September 2026 was 14.3%, up 3.4 percentage points from fiscal 2025 (10.8%). Over the past ten years it has ranged from −31.1% (fiscal 2022) to 48.8% (fiscal 2020); the current reading is higher than 73% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.8% | 34.93 |
| FY2024 | −24.1% | (17.15) |
| FY2023 | −6.94% | 24.20 |
| FY2022 | −31.1% | (67.25) |
| FY2021 | 36.1% | (12.68) |
| FY2020 | 48.8% | 12.81 |
| FY2019 | 36.0% | 25.46 |
| FY2018 | 10.5% | 6.08 |
| FY2017 | 4.44% | 3.41 |
| FY2016 | 1.03% | (3.64) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation compare | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| PEN Penumbra, Inc. compare | 10.7% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| GKOS Glaukos Corporation compare | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BIO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement